Purchase this article with an account.
B. Pemp, D. Schmidl, M. Lasta, G. Weigert, G. Garhofer, L. Schmetterer; The Phosphodiesterase Inhibitor Moxaverine Increases Ocular Blood Flow in Patients With Age-Related Macular Degeneration and in Age-Matched Healthy Subjects. Invest. Ophthalmol. Vis. Sci. 2010;51(13):5034.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Results from recent studies have shown that the unspecific phosphodiesterase inhibitor moxaverine increases choroidal blood flow (ChBF) in young healthy subjects and in patients with primary open angle glaucoma. There is some evidence that reduced ChBF may contribute to the development of age-related macular degeneration (AMD). Therefore we tested whether moxaverine increases ocular blood flow in patients with AMD and in control subjects with healthy eyes.
20 patients with dry AMD and 20 age-matched healthy subjects were included in this study. 150 mg moxaverine was administrated intravenously over 30 minutes. Retinal vessel diameters were measured using the Dynamic Vessel Analyzer, ChBF and optic nerve head blood flow (ONHBF) were measured using laser-Doppler flowmetry, retrobulbar blood velocities were assessed using colour Doppler imaging. Measurements were performed before and 30, 60 and 90 minutes after the start of drug administration.
Moxaverine increased ChBF by 10 ± 23% (p = 0.050), ONHBF by 15 ± 33% (p = 0.049), mean flow velocity (MFV) in the ophthalmic artery by 27 ± 39% (p < 0.001) and MFV in posterior ciliary arteries by 30 ± 39% (p 0.30). Moxaverine had no effect on retinal vessel diameters.
A single dose of systemic moxaverine increases ocular blood flow in patients with AMD and in age-matched subjects with healthy eyes. Further studies are needed to investigate whether a long-term use of moxaverine is beneficial in treatment or prevention of AMD.
Clinical Trial: :
This PDF is available to Subscribers Only